Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 15 points (+0.1%) at 14,565 as of Thursday, Apr 4, 2013, 12:35 p.m. ET. During this time, 278 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 604.4 million. The NYSE advances/declines ratio sits at 1,512 issues advancing vs. 1,354 declining with 153 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting an eight-cent gain (+0.3%) bringing the stock to $29.12. This single gain is lifting the Dow Jones Industrial Average by 0.61 points or roughly accounting for 4.1% of the Dow's overall gain. Volume for Pfizer currently sits at 16.8 million shares traded vs. an average daily trading volume of 31.6 million shares. Pfizer has a market cap of $210.04 billion and is part of the health care sector and drugs industry. Shares are up 15.8% year to date as of Wednesday's close. The stock's dividend yield sits at 3.3%. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 23.2, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.